塞拉万斯生物制药

关于 Theravance Biopharma(Delisted)

Theravance Biopharma 公司 is a biopharmaceutical company 专注于 the 开发 and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has 开发 FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company 运营 in a single 部分, the 开发 and commercialization of human therapeutics, and 运营 in the United States, which generates maximum revenue, and Europe.

首席执行官

Mr. Rick E. Winningham

员工人数

90

财年结束日

12-31

官方网站

theravance.com

公司概况

交易所

US

股票代码

TBPH

市值排名

#3330

上市日期

2015-10-26

市值

884.18M

流通市值

440.57M

总股数

51.92M

流通股数

25.87M

行业与主题板块

浏览全部行业与主题板块